These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 7915824)

  • 1. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
    Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF
    N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
    Pascal-Vigneron V; Weryha G; Bosc M; Leclere J
    Presse Med; 1995 Apr; 24(16):753-7. PubMed ID: 7784413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
    Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG
    J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
    Ciccarelli E; Giusti M; Miola C; Potenzoni F; Sghedoni D; Camanni F; Giordano G
    J Clin Endocrinol Metab; 1989 Oct; 69(4):725-8. PubMed ID: 2570790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of hyperprolactinemic amenorrhea with cabergoline].
    Fideleff HL; Holland ME; Chervin A; Gurucharri C; Sinai I
    Medicina (B Aires); 1997; 57(6):657-61. PubMed ID: 9674185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabergoline and hyperprolactinaemia: new preparation. Better than bromocriptine.
    Prescrire Int; 2000 Feb; 9(45):195-7. PubMed ID: 11503793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
    Giusti M; Porcella E; Carraro A; Cuttica M; Valenti S; Giordano G
    J Endocrinol Invest; 1994 Jan; 17(1):51-7. PubMed ID: 7911813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination.
    Motazedian S; Babakhani L; Fereshtehnejad SM; Mojthahedi K
    Indian J Med Res; 2010 May; 131():670-4. PubMed ID: 20516539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabergoline in the long-term therapy of hyperprolactinemic disorders.
    Ferrari C; Paracchi A; Mattei AM; de Vincentiis S; D'Alberton A; Crosignani P
    Acta Endocrinol (Copenh); 1992 Jun; 126(6):489-94. PubMed ID: 1642081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
    Ferrari C; Mattei A; Melis GB; Paracchi A; Muratori M; Faglia G; Sghedoni D; Crosignani PG
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
    Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
    Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine agonist therapy in hyperprolactinemia.
    Webster J
    J Reprod Med; 1999 Dec; 44(12 Suppl):1105-10. PubMed ID: 10649819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
    Webster J
    Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
    Rains CP; Bryson HM; Fitton A
    Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.